Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland.
Ann Nutr Metab. 2017;71(1-2):91-98. doi: 10.1159/000477913. Epub 2017 Jul 22.
BACKGROUND/AIMS: Cystic fibrosis (CF) liver disease is the third most frequent cause of death in CF patients. Although it alters fatty acid (FA) metabolism, data concerning the profile of FA in CF patients with liver cirrhosis is lacking. This study aimed to assess the FA composition of serum phospholipids in CF patients with and without liver cirrhosis.
The study comprised 25 CF patients with liver cirrhosis and 25 without it. We assessed Z-scores for body height and weight, lung function, exocrine pancreatic sufficiency and colonization with Pseudomonas aeruginosa. FAs' profile of serum glycerophospholipids was quantified by gas chromatography mass spectrometry.
In CF patients with liver cirrhosis, the levels of C16:0 were higher and the amounts of C20:2n-6, C20:3n-6, C20:4n-6, and all the n-3 polyunsaturated FAs (PUFAs) (C18:3n-3, C20:5n-3, C22:5n-3, C22:6n-3) were lower than those in CF subjects without liver cirrhosis. The n-6/n-3, C20:4n-6/C18:2n-6, total n-6/C18:2n-6, C20:5n-3/C18:3n-3 and total n-3/C18:3n-3 ratios did not differ between the 2 groups.
Liver cirrhosis may associate with profound abnormalities in the composition of serum glycerophospholipids FAs in CF patients. None of the analyzed clinical factors could explain the greater prevalence of low levels of PUFAs in this CF subgroup.
背景/目的:囊性纤维化(CF)肝疾病是 CF 患者的第三大常见死亡原因。尽管它改变了脂肪酸(FA)代谢,但缺乏有关 CF 合并肝硬化患者 FA 谱的数据。本研究旨在评估 CF 合并和不合并肝硬化患者血清磷脂中 FA 的组成。
本研究包括 25 例 CF 合并肝硬化患者和 25 例不合并肝硬化患者。我们评估了身高和体重的 Z 分数、肺功能、外分泌胰腺充足性和铜绿假单胞菌定植。通过气相色谱质谱法定量血清甘油磷脂中 FA 的谱。
在 CF 合并肝硬化患者中,C16:0 的水平较高,而 C20:2n-6、C20:3n-6、C20:4n-6 和所有 n-3 多不饱和脂肪酸(PUFA)(C18:3n-3、C20:5n-3、C22:5n-3、C22:6n-3)的水平低于 CF 不合并肝硬化患者。n-6/n-3、C20:4n-6/C18:2n-6、总 n-6/C18:2n-6、C20:5n-3/C18:3n-3 和总 n-3/C18:3n-3 比值在两组间无差异。
肝硬化可能与 CF 患者血清甘油磷脂 FA 组成的深刻异常有关。在这个 CF 亚组中,分析的临床因素均不能解释 PUFAs 水平较低的更常见现象。